IMPORTANCE Type 2 diabetes (T2D) is increasingly common in young individuals. Primary prevention and screening among children and adolescents who are at substantial risk for T2D are recommended, but implementation of T2D screening practices in the pediatric primary care setting is uncommon.
We implemented the ADA screening guidelines for T2D at pediatric primary care practices by using a computer decision support system developed by our research group: the Child Health Improvement Through Computer Automation (CHICA) system. 5 The application of a computer decision support system to the screening and diagnosis of T2D in youths is relatively unexplored. 3 We hypothesized that the system could help overcome the barriers to screening for prediabetes and T2D described by pediatricians. Our objective was to determine the feasibility and effectiveness of the CHICA system in identifying at-risk youths and coordinating the screening for and diagnosis of prediabetes and T2D via a randomized clinical trial.
Methods
This study was performed in 4 primary care practices in the Eskenazi Health Center Primary Care system from January 1, 2013, through December 1, 2016. The trial protocol (available in the Supplement) was approved by the institutional review board of Indiana University. A waiver of consent was obtained from the institutional review board because (1) little risk accrued in supplying physicians with guidelines; (2) study procedures were within the standards of care; (3) informing families that they may be part of a study could bias their response to screening questions; and (4) obtaining informed consent from every patient was impracticable and presented a higher risk for loss of patient confidentiality.
Participants
Our intervention was aimed at physicians. However, the outcomes of interest are patient based. The patients in this study were 10 years or older and were automatically cluster randomized to the control or the intervention group based on which of the 4 clinics they attended. No patients were contacted by researchers, their physician, or other staff regarding the study. The ADA recommends that youths be screened for T2D if they have a body mass index (BMI) (calculated as weight in kilograms divided by height in meters squared) at or above the 85th percentile for age and sex and 2 or more additional risk factors starting at 10 years of age or at the onset of puberty, whichever occurs first.
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Study Design
We conducted a cluster-randomized clinical trial in which we compared screening for T2D among youth meeting ADA criteria between the intervention and control practices ( Figure 1 ). Four clinics were enrolled by randomizing the 2 largest clinics to the intervention and control conditions by a coin toss. Two additional clinics were alternately assigned to the intervention and control conditions such that study populations 
Randomized
The final analysis included 565 patients with risk factors for type 2 diabetes (T2D). BMI indicates body mass index.
would be similar in size. Intervention clinics used the system that incorporated the CHICA T2D module, which included T2D guidelines. Control clinics used the traditional CHICA system that did not include T2D guidelines. Seventeen physicians practiced at the intervention sites and 12 practiced at the control sites. Although randomization at the physician or patient level may have been sample-size efficient, we randomized by clinic because contamination was a concern. If we randomized by physician, the study would be complicated when patients were seen by different physicians in and out of the study. If we randomized by patient, the on-and-off use of the CHICA T2D module would complicate physician work flow. 6 Both randomization methods could lead to contamination.
CHICA System
The CHICA system has been described in detail previously. 5, [7] [8] [9] [10] CHICA is a computer decision support system coupled with an electronic medical record (EMR) for pediatric primary care and chronic disease management. CHICA uses a prescreener form containing 20 questions for parents. Questions are based on national guidelines, and selection is determined by applying logic rules to data contained in the individual's EMR. 7 Aphysician worksheet contains as many as 6 prompts that include check box responses for the physician's assessment and actions. The prescreener questions and physician prompts are programmatically chosen by the patient's age and EMR data. The CHICA T2D module prescreener included information on family history, race or ethnicity, and maternal gestational diabetes, and physician prompts included documenting signs and conditions associated with insulin resistance. The EMR contained diagnostic codes, orders, prescriptions, and laboratory data from the statewide health information exchange, the Indiana Network for Patient Care. 11 CHICA was implemented on tablets for the prescreener form, and the physician worksheet switched from a paper to an online format during the study.
Intervention: The CHICA T2D Module
The outline for the CHICA T2D module is provided in Figure 2 and Figure 3 . The BMI data were analyzed by the CHICA system; when the BMI was at or above the 85th percentile, a prompt on the physician worksheet asked whether the patient had any symptoms or conditions associated with insulin resistance. This information was analyzed along with the data from the prescreener form to determine whether the patient had 2 or more risk factors for T2D. If at least 2 risk factors were present, the physician was prompted to order measurement of fasting plasma glucose (FPG) and hemoglobin (HbA 1c ) levels. Measurements of both FPG and HbA 1C levels were included because whether similar FPG and HbA 1C cutoff points are appropriate for the pediatric and adult populations remains unclear, and controversy exists over which is the most appropriate screening test in pediatrics. 4, 12, 13 Paper educational materials regarding the importance of screening for T2D and instructions for the blood test were printed and provided to families. The CHICA T2D module generated automated telephone calls about laboratory testing (with instructions for fasting) and follow-up appointments. Reminder telephone calls were unique to the CHICA T2D module. If the FPG level was greater than 125 mg/dL (to convert to millimoles per liter, multiply by 0.0555) or the HbA 1C level was at least 6.5% (diabetes range; to convert to a proportion of total hemoglobin, multiply by 0.01), a prompt instructed the physician to refer the patient to pediatric endocrinology for further evaluation and/or treatment; a referral page was generated if the physician responded yes to the prompt. If screening results were at or near the prediabetes range (ie, FPG level of 95-125 mg/dL and HbA 1c level <6.5% or FPG level ≤125 mg/dL and HbA 1c level of 5.7%-6.4%), a prompt was generated for the physician to order an oral glucose tolerance test (OGTT) and follow-up appointment. The rationale for the OGTT at these FPG and HbA 1c cut points was that the reference standard for the diagnosis of prediabetes and T2D in youth is unknown and additional information on glucose tolerance would be helpful in determining risk and treatment.
14 We used 95 rather than 100 mg/dL as the cut point for FPG level because this population was at high risk for T2D, and the FPG level is often not elevated in prediabetes and early T2D, when hyperglycemia occurs only in the postprandial state. 15 If the OGTT result indicated diabetes (OGTT result, >199 mg/dL), a prompt instructed the physician to refer the patient to pediatric endocrinology, and a referral was faxed if the physician responded yes to the prompt. For screening test results consistent with prediabetes, the pediatrician was prompted to order a 6-month follow-up appointment. If an appointment was scheduled, the CHICA T2D module generated a reminder telephone call about this appointment. During follow-up appointments, the pediatrician was prompted to provide the patient and the patient's parent or guardian with nutrition and exercise recommendations, and paper educational handouts related to these topics were generated. If patients did not attend follow-up appointments, these handouts were not provided.
Main Outcomes
The primary outcome was the percentage of youths identified with documented risk factors for T2D. We hypothesized that the use of the prescreener form would result in the identification of more risk factors and therefore identify more youths at risk. To determine which youths were truly at risk (regardless of physician identification), data were collected via EMR abstraction and review of CHICA data for the intervention and control clinics. A random sample of 350 EMRs of youths 10 years or older per clinic was used for a total of 700 per study arm. Research assistants were trained to review the EMR for information related to screening and diagnosis of T2D. In the case of multiple visits by the same patient during the study period, the EMR was eligible for review once. The secondary outcome was the percentage of youths who had laboratory tests ordered and completed (screening). Whether a patient underwent screening for T2D was identified as yes when an FPG or an HbA 1c level or both were documented in the EMR.
Sample Size and Power Estimation
We estimated the real screening rate to be approximately 10% in our clinics under standard practice. Based on a literature review, we expected that more than 20% of the youths 10 years or older would have a BMI at or above the 85th percentile and at least 2 risk factors for T2D. 16, 17 We would have 80% power to detect a 10% difference in the proportion of children who would undergo screening for T2D between the intervention and control groups with a total effective sample size of 438 patients. Because the randomization was at the clinic level, responses from patients in the same clinic were likely correlated, causing a decrease in analytical power. The magnitude of power reduction depends on the level of heterogeneity of the clinical sites; such heterogeneity is often characterized by the intraclinic correlation. Although we did not anticipate significant variability in the 4 clinics, we assumed intraclinic correlation of no more than 0.006. Using this conservative estimate, we needed to review the EMRs of 317 children per clinic. To accommodate a 10% rate of missing BMI data, we increased the sample size to 350 per clinic.
Statistical Analysis
Baseline characteristics of the participants were compared using the χ 2 test or the Fisher exact test for categorical outcomes and the Wilcoxon rank sum test for age because the distribution was skewed. Logistic regression models estimated associations between the intervention and the odds of screening. Clinic-level random intercepts accommodated the potential dependence of responses from in the same clinic. We did not expect correlation due to clustering of participants in clinics. Covariates (age, sex, race, and insurance) were screened for inclusion by testing whether the groups showed a difference at P < .10. Group differences in primary and secondary outcomes were adjusted for age, sex, race, and insurance when a covariate was significant at P < .10. Analyses were performed using SAS software (version 9.4; SAS Institute Inc).
Results
This study included 1423 EMRs abstracted for eligibility. To assess the reliability of EMR abstraction, a random sample of 20% of the records was abstracted twice. The interrater reliability was 93%, and the κ statistic was 0.87. Of these, 54 (3.8%) were missing BMI data and were excluded, leaving 1369 for analysis (712 One hundred thirty-two patients underwent screening for T2D, resulting in a screening rate for the entire study population of 9.6%. The adjusted odds ratio of screening in the intervention group was 3.7 (95% CI, 1.8-7.7) ( Table 2) . Among the 565 youths meeting criteria, physicians ordered any screening test for T2D for 115 (20.4%). The adjusted odds ratio for the intervention group was 4.6 (95% CI, 1.5-14.7) compared with the control group (Table 2) .
We found a low rate of ordering FPG for screening ( Table 2) . None of the documented FPG levels was greater than 125 mg/dL (diabetes range). One of 3 control patients (33.3%) who underwent FPG screening had an FPG level in the prediabetes range, and 2 of 9 intervention patients (22.2%) who underwent FPG screening had FPG levels in the prediabetes range.
The rate of ordering HbA 1c assessment among those meeting ADA criteria was higher than that for FPG assessment (Table 2) . Ninety-eight of 565 eligible youths (17.3%) underwent HbA 1c screening. One of the documented HbA 1c levels was at least 6.5% (diabetes range) in the intervention group. Of the control patients undergoing screening, 5 (31.2%) had HbA 1c levels ranging from 5.7% to less than 6.5% (prediabetes range), and 13 of 63 intervention patients (20.6%) undergoing screening had HbA 1c levels in the prediabetes range. No patients were scheduled for OGTT.
The proportion of youths who were scheduled for a follow-up appointment with their pediatrician is shown in Table 2 . The proportions of youths who actually attended a scheduled follow-up appointment were 38 of 201 control patients (18.9%) and 45 of 153 intervention patients (29.4%). One patient was referred to pediatric endocrinology.
Discussion
The CHICA T2D module more than quadrupled the rates of screening for T2D among youths with a BMI at or above the 85th percentile and 2 or more risk factors at well-care visits, as recommended by the ADA guidelines. The CHICA T2D module was also associated with greater attendance at follow-up appointments. The intervention did not lead to more patients being diagnosed with prediabetes or T2D, but our study was not powered to detect changes in clinical outcomes. The CHICA system is unique because it permits us to insert guideline-based care into existing clinic practices in a format that integrates easily into routine pediatric care. The CHICA T2D module can therefore overcome many barriers to the T2D screening process. Computer decision support systems have been shown to improve adherence to practice recommendations in pediatric primary care and hospital settings. 9,19-22 However, such systems are only beginning to be implemented for patientcentered medicine based on information available in the EMR. 10 Screening for T2D in youths has not been studied before using this technology. Our findings not only highlight the potential effect of computer decision support for pediatricians caring for populations at high risk for T2D but also set the stage for introducing these systems in other EMRs and for other chronic conditions. This population was enriched with youth of minority race or ethnicity with a high rate of overweight and obesity (BMI ≥85th percentile). In comparison, the 2011 to 2012 National Health and Nutrition Examination Survey data for nonHispanic black youths showed that 38.1% aged 6 to 11 years and 39.8% aged 12 to 19 years had a BMI at or above the 85th percentile; data for Hispanic youths showed that 46.2% aged 6 to 11 years and 38.1% aged 12 to 19 years had a BMI at or above the 85th percentile. 23 The proportion of youths meeting BMI criteria and having at least 2 other risk factors for T2D in our study was 41.3%. However, fewer than half of the youths who met this criterion had laboratory tests performed. testing is preferred, although research is necessary to determine optimal screening strategies for youth populations at high risk for T2D.
Limitations
This study has limitations that warrant consideration. Although we conducted a large randomized clinical trial, only 4 clinics were involved. We cannot ensure that no differences between the control and intervention groups existed in BMI distribution, although all patients in this study had BMI at or above the 85th percentile or no differences in other coexisting conditions. We also could not determine correlation due to clustering of patients in clinics. The age distribution of the patients was skewed toward younger adolescents because many patients older than 15 years were seen in a separate clinic that did not use CHICA. This separation may have led to lower rates of prediabetes and T2D detected by screening procedures. The CHICA system is also currently used only in Eskenazi Health and Indiana University Health primary care settings. We are working to provide CHICA as a web service that can interface with commercial EMR systems. For dissemination, current ADA recommendations, which treat OGTT results and FPG and HbA 1c levels as equivalent and do not recommend sequential testing in asymptomatic individuals, should be used. 32 The FPG cut point of 100 mg/dL should be used instead of 95 mg/dL, as was used in this study.
Conclusions
Use of a computerized clinical decision support system to automate the identification and screening for T2D can help overcome barriers to the screening process. The system significantly increased rates of screening among youths who met the ADA criteria and adherence to follow-up appointments with primary care clinicians. Whether the system can help improve health outcomes in youth diagnosed with prediabetes or T2D remains to be determined. During phase one of this project, we will make several additions and enhancements to the existing CHICA system within these clinic sites. Specifically, rules will be written for the addition of screening questions to the pre-screener form and diagnosis instructions will be programmed for the physician worksheet. Additionally, we are proposing several technical enhancements to the current CHICA system including automated physician order generation and automated reminder phone calls to patients. This technical work will take place in year one of the project, and based on our past experience, we expect this work to take less than 12 months to complete.
C.3.1.1 Program the CHICA Type 2 Diabetes Module
The overall outline for the CHICA type 2 Diabetes Module that will be programmed into the CHICA system is provided in Figures 1 and 2 below.
Information with regard to family history of type 2 diabetes, race/ethnicity, and maternal history of gestational diabetes will be gathered for every patient, regardless of age, by asking these questions of parents on the prescreener form (Figure 1, Box 1) . This data will then be utilized at a later point by the CHICA system when a child is age 10 or older and presents to the clinic. Data regarding the child's BMI at that time will be analyzed by the CHICA system ( Figure 1, Box 2) . If the child's BMI is greater than the 85 th percentile (Figure 1, Box 3) , a prompt will appear on the provider worksheet asking the clinician whether the child has any symptoms or conditions associated with insulin resistance (Figure 1, Box 4) . This information along with the data gathered previously from the pre-screener form will be analyzed to determine whether the child has 2 or more risk factors for the development of type 2 diabetes (Figure 1, Box 5 ). If at least 2 risk factors are present, then an automated physician order will be generated for a FPG and HbA1C (Figure 1, Box 6 ). Patient educational material will be printed out and provided to the family regarding the importance of screening for type 2 diabetes and instructions for the blood test (Figure 1, Box 6 ). The CHICA system will also recommend that the patient be scheduled for a follow-up visit for the same day as the lab draw occurs, (Figure 1, Box 6 ) and the patient will receive a CHICA generated reminder telephone call about the lab testing (with instructions for fasting) and follow-up appointment (Figure 1, Box 7) . At the follow-up appointment if FPG is greater than 125 or HbA1C is greater than or equal to 6.5% (Figure 2 , Box 1), a prompt will appear on the physician worksheet instructing the physician to refer the patient to pediatric endocrinology, and a referral will be automatically faxed to endocrinology (Figure 2 , Box 9). At this time a page to the pediatric endocrinology doctor on call will be initiated automatically by the CHICA system so that the pediatrician can discuss the need for further work-up or immediate referral in the case of symptoms requiring emergent treatment. Additional work-up will be directed by the pediatric endocrinologist (Figure 2 , Box 10).The CHICA system will generate an automated reminder telephone call to the patient regarding their scheduled appointment with pediatric endocrinology (Figure 2, Box 11) . Following the appointment with endocrinology, feedback regarding management plans will be provided to the pediatrician from the endocrinologist through a structured letter that was generated and faxed by the CHICA system (Figure 2 , Box 12). This faxed letter will be received directly by the CHICA system, digitally interpreted, and the data will be automatically deposited into CHICA for display on the provider worksheet at the patient's next appointment with their pediatrician (Figure 2 , Box 13). If a child's initial FPG is between 100 and 125 or HbA1C is between 5.7 -6.4%, then an automated physician order will be generated for an OGTT (Figure 2, Box 3) . The CHICA system will also instruct that the patient be scheduled for a follow-up visit for the same day as the lab draw occurs (Figure 2, Box 3) , and the patient will receive a CHICA generated reminder telephone call about the lab testing (with fasting instructions) and followup appointment (Figure 2, Box 4) . If the OGTT is indicative of diabetes (OGTT > 199) (Figure 2, Box 5) , then a prompt will appear on the physician worksheet instructing the physician to refer the patient to pediatric endocrinology, and a referral will be automatically faxed (Figure 2, Box 9) . In addition, a page to the pediatric endocrinology doctor on-call will be initiated automatically by the CHICA system so that the pediatrician can discuss the need for further work-up or immediate referral in the case of symptoms requiring emergent treatment. If the OGTT is indicative of pre-diabetes (OGTT between 140 and 199) (Figure 2, Box 6) , additional work-up, including a repeat OGTT, will be directed by the pediatric endocrinologist (Figure 2, Box 8) .Once again automatic patient reminder telephone calls will be initiated, and feedback letters from endocrinology will be faxed directly into the CHICA system and available to the pediatrician at the patient's next appointment (Figure 2, Box 10-13) .
If the OGTT is normal (Figure 2 , Box 6) then the pediatrician will be prompted on the physician worksheet to provide the patient with diet and exercise recommendations, and just-in-time educational handouts will be generated for the patient related to these topics (Figure 2, Box 14) . The pediatrician will be alerted that these children are at high risk for developing type 2 diabetes due to risk factors and history of an abnormal FPG or HbA1C, and deserve more frequent follow-up. The CHICA system will instruct that the patient be seen again within 6 months ( Figure 2 , Box 15). At that time, they will have follow-up lab tests performed (fasting glucose, HbA1C, and referral to pediatric endocrinology if they meet the criteria outlined above). The patient will receive a CHICA generated reminder telephone call about this 6 month follow-up appointment (Figure 2 , Box 16).
C.3.1.2 Technical Enhancements
A new capability will be added to the CHICA system in the form of automated reminder telephone calls to patients for return laboratory testing and follow-up appointments. CHICA software will initiate a programmatic request to a third party Voice over IP (VoIP) based auto dialer software. The auto dialer will initiate the call from a preconfigured list of telephony service provider(s) such as Skype (www. Skype.com) or others using the industry standard Session Initiation Protocol (SIP). We will evaluate third party auto dialers for advanced features like "reading a script".
Another new feature of the CHICA system will be automated physician order generation for HbA1C and FPG tests. When the CHICA system determines that a patient meets the criteria for type 2 Diabetes it will generate a just-in-time document using MLMs that contains the order. This just-in-time can be printed on paper to be handed to the patient, faxed to a predetermined lab, or called in using telephony interface.
While the CHICA system currently includes fax capabilities, which allows for faxed information to be deposited directly into CHICA and the medical record, we will be expanding these capabilities through the addition of automated faxed referrals from the CHICA system to pediatric endocrinologists. We will also program CHICA to receive, interpret, and deposit data from the pediatric endocrinologist regarding management plans into the CHICA database through a faxed structured letter.
C.3.1.2 Validation of the CHICA Type 2 Diabetes Module and Process to Address Technical Issues
We began building the CHICA system in 2002, and it has been in active operation since 2004. Therefore, we have a great deal of previous experience validating rule sets and addressing technical issues pertaining to database design, queries, parsing, annotation, context analysis, and missing data. We are aware of the many potential barriers/pitfalls that can be encountered during this process and we therefore have developed a process to overcome these potential issues and to maximize the benefit of the technology.
All rules and rule sets developed for use with the CHICA system undergo thorough testing prior to implementation within the "live" CHICA system. We begin by reviewing the logic behind all rules and rule sets in the CHICA User's Group (CHUG)meeting, an expert panel consisting of both health care providers and CHICA programmers to make sure that they appear valid. We then proceed to simulations, running the rules with test patients to make sure that they are triggered accurately. After rule deployment, we meet monthly with the CHUG, and review all CHICA process data in weekly team meetings to make sure that randomization and rule firing appears valid. Should any issues arise, we will strive to implement fixes in a timely manner.
We have (and will continue to have) one programmer who is always on call to perform technical support, in addition to this, a less technical member of the CHICA team will rotate full time through the clinics to assess CHICA's use and note any issues or problems for the full team to address. Further, the CHICA team leader and one of the programmers meets with physicians and staff on a regular schedule at the clinics over breakfast or lunch to allow clinic personnel to address members of the CHICA team directly. Phase two of this proposed project consists of the randomized controlled trial of the CHICA Type 2 Diabetes Module (built in Phase one), evaluating primarily process measures. Work on this phase of the project will begin in quarter 1 of year 2 and will continue through quarter 2 of year 4.
C.3.2.1 Randomization
Presently, the CHICA system is utilized in four primary care practices affiliated with the Indiana University Medical Group-Primary Care (IUMG-PC) practice network. In 2009, these four clinics (Wishard Pediatric Primary Care, Pecar Health Center, Blackburn Health Center, and Forest Manor Health Clinic) hosted around 7000 patient visits for children ages 10 and older, the target population for this study. However, children within the age range with a pre-existing (pre-intervention) diagnosis will be excluded from the study. This corresponds to over 3,800 unique patients. Therefore over a 24 month timeframe we can conservatively anticipate that at least 4000 unique patients ages 10 and older will be seen in these four clinic sites. Additionally, these four clinic sites serve a large minority population, who are at greatest risk for developing type 2 diabetes (44% Black, 21% Hispanic).
The randomized controlled study will be conducted in these four clinic sites; two of the clinics will function as an intervention group and two will function as the control group. The unit of randomization will be the primary care clinic, but the unit of analysis will be the individual patient. Allocation of clinics to intervention or control groups will involve a randomization scheme in which the clinics will be ranked by the number of physicians staffing the clinic. One of the two largest clinics will be randomized to the intervention and the other to the control condition, and subsequent clinics will be alternately assigned to intervention and control such that each clinic can be matched to its most similarly sized clinic.
We chose a cluster randomization by clinic because contamination is a major concern. If we randomize at the physician level, physicians in the same clinic who are assigned to different treatment arms might communicate regarding the CHICA Type 2 Diabetes Module in terms of its operation and consequences, which would contaminate the control arm. Similarly, if we randomize at the patient level, physicians will tend to carry intervention methods to control patients, copying and utilizing intervention materials. Indeed, this has been our experience with other studies of the CHICA system. 29, 30, 33 Moreover, the on and off usage of the CHICA Type 2 Diabetes materials such as the physician worksheet and just-in-time handouts leads users to think that CHICA is malfunctioning.
Although this cluster randomization scheme imposes a number of challenging issues in terms of study design and data analysis, it is the optimal approach due to the reasons stated above. The limitation of randomization at the clinic level is cluster effects requiring larger sample sizes and potential bias caused by unknown characteristics related to the outcome that are differentially distributed in the four clinics. We have taken the clustering effect of the cluster randomization scheme into consideration for the determination of the sample size and the analysis plan (See sections C.3.2.8 and C.3.2.9).
C.3.2.2 Intervention Group
The two intervention clinic sites will have the CHICA system AND be provided access to the newly developed CHICA Type 2 Diabetes Module, the flow of which is depicted in Figures 1 and 2 and previously described in section C.3.1.1.
C.3.2.3 Control Group
The two control clinics will have the CHICA system but will NOT have access to the CHICA Type 2 Diabetes Module. The CHICA system will notify the physician of the child's BMI percentile on the physician worksheet. However, the CHICA system will not ask for any additional information related to risk factors for type 2 diabetes on the pre-screening form, no advice will be provided to the physician on the physician worksheet, nor will justin-time documents or automated reminder calls be made available. Identification of patients at risk for type 2 diabetes and care of those patients will occur through routine practices for that clinic.
C.3.2.4 Recruitment
We will ask for a waiver of consent for this portion of the study as 1) there is little risk involved in supplying physicians with guidelines of care, 2) study procedures are within standards of usual care, 3) informing families that they may be part of a type 2 diabetes study could bias their response to screening questions and invalidate any and all results of the project, and 4) obtaining informed consent from the many thousands of patients who are seen at IUMG-PC clinics would be difficult and would itself create, because of the paperwork that would be required, a much higher risk of loss of patient confidentiality.
C.3.2.5 Measures
For Aim 2 of this project the primary outcome measure of interest is the percent of children ages 10 and older with documented risk factors for type 2 diabetes. The table below shows both our primary outcome measure along with secondary process and outcome measures of interest. 
C.3.2.6 Data Collection Procedures
In order to evaluate the process measures identified above, data will be collected via medical record abstraction and through review of CHICA data for both the intervention and control clinics. As the primary process measure of interest for this Aim is the percent of children ages 10 and older with documented risk factors for type 2 diabetes, a patient's chart will be eligible for chart abstraction if the child is age 10 or older. We will select a random sample of 250-350of these charts per clinic for a total of up to 750 per study arm (See Section C.3.2.7 for Sample Size calculation).
Research assistants (RAs) will be trained to review both the electronic medical record and paper charts for a variety of information related to screening and diagnosis of type 2 diabetes. To prepare for chart abstractions, we will secure copies of paper charts and access electronic charts, including charts of children identified with a type 2 diagnosis in CHICA or RegenstriefMedical Record System.To assess the reliability of chart abstraction, a random sample of 20% of the charts will be abstracted twice.
Eligibility and Consent for Physician Population: All physicians (including residents) practicing in the targeted clinic sites (approximately 50) who utilize the CHICA system will be eligible to participate in this study by default. We will obtain informed verbal consent because data will be collected from surveys of physicians (non-patient adults) without identifying information. The survey, which will be hand-delivered to physicians by PResNet staff, includes 5 questions, and require approximately 5-10 minutes to complete. The survey will incorporate Likert scales to measure physician's use of the ADA guidelines for screening, diagnosing, and treating childhood type II diabetes. PResNet staff will be responsible for data entry and reporting of these data to study investigators.
C.3.2.7 Sample Size and Power Estimation
We determined the sample size to ensure adequate power to test the efficacy of the CHICA Type 2 Diabetes Module, as proposed in Specific Aim 2. The primary outcome is type 2 diabetes screening, measured at the subject level. The current screening rate for type 2 diabetes is known to be low. We estimate the screening rate to be approximately 10% in our clinics.
In a study of a predominantly low-income, Mexican American population, Drobac and colleagues reported that 20% of the children aged 10 to 18 years had a BMI above 85 percentile and at least 2 additional risk factors for type 2 diabetes, including family history of type 2 diabetes, high-risk race/ethnicity, and evidence of insulin resistance. 8 Kong and colleagues considered a BMI above 85th percentile as a fourth risk factor and reported that 60% of the children had two or more risk factors while 27% had three or more risk factors. 35 We expect that more than 20% of the children ages 10 and older will have a BMI above the 85th percentile and at least two of the four risk factors and hence will be screened in the intervention group.
If randomization were performed at the subject level, using a chi-square test and setting the alpha level at 0.05, we would have 80% power of detecting a 10% difference in the proportion of children screened for type 2 diabetes between the intervention and control groups with a total effective sample size of 438 patients.
Since the randomization is at clinic level, responses from subjects within the same clinic are likely correlated, causing a decrease in analytical power. The magnitude of power reduction depends on the level of heterogeneity of the clinical sites; such heterogeneity is often characterized by the intra-clinic correlation. Although we do not anticipate much variability in the four participating clinics, we will assume that the screening rate using standard care is 9% and 11% for two clinics and 10% for the remaining two clinics. Conservatively, we have estimated that the numbers of children age 10 or older seen in the four clinics are approximately 400, 500, 800, and 1500. This gives an intra-clinic correlation of no more than 0.006. Using this conservative estimate of intra-clinic correlation, we need to enroll 317 children per clinic. Note that this is a conservative sample size also because our pseudo randomization scheme is a matched-pair design, which has been shown to provide an improved power than the unmatched studies.
36 Based on our past experience, we do not anticipate dropout to be more than 10%. To compensate for the potential sample attrition, we will inflate the estimated sample size to 250-350 per clinic.
